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ABSTRACT

INTRODUCTION: Multi-drug resistant tuberculosis (MDR-TB) poses a great threat to the
eradication of TB. In the US, MDR-TB is faced with inadequate diagnostic tools and long and
expensive treatment regimens. Therefore, preventing the disease is the key to saving lives and
resources. Social and behavioral variables play a big part in this prevention. It is important to
determine the social factors that may lead to MDR-TB in order to set up prevention programs and
more efficient treatment regimens.
AIM: This study was conducted to ascertain the social determinants of MDR-TB in the US
between the years of 2005 and 2009 to better equip public health officials to deal with this
growing threat.
METHODS: This study used the Centers for Disease Control and Prevention (CDC) Online
Tuberculosis Information System (OTIS) database to find associations between certain social
variables and MDR-TB. The variables that were tested were whether or not the individual had
lived in a correctional facility for the past year; HIV status; homelessness; whether or not the
individual had an occupation; and whether the individual was foreign-born or US-born. An
unadjusted odds ratio (OR) was calculated to find this association. The variables were then
stratified with age; sex; race; age and race; age and sex; and age, sex, and race to see whether or
not the strata were confounders.
RESULTS: The variables of having lived in a correctional facility and homelessness were found
to be associated with MDR-TB. However, all of the strata were found to be confounders for this
relationship. Having HIV and being US-born were not found to be associated with MDR-TB. All
of the strata for HIV were found to be confounders. But for place of birth, stratifying by age, sex,
and both age and sex were not confounders. The rest of the strata were. The OR for occupation
versus MDR-TB was almost at 1, meaning that those with a job and those without a job had
almost equal odds of having MDR-TB. Effect modification was present for the strata in all
variables, meaning that the risk of having MDR-TB varied with each different age, sex, and racial
group.

DISCUSSION: Results from this study showed which variables were more likely to be
associated with MDR-TB in the US between the years of 2005 and 2009. However, when
compared to the literature that exists, the results showed that more research needs to be done to
properly ascertain this relationship. Using this study, public health officials can identify which
populations to focus prevention efforts on.
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CHAPTER 1
INTRODUCTION
The eradication of tuberculosis (TB) has been made much more difficult with the
emergence of multidrug-resistant TB (MDR-TB). The World Health Organization
(WHO) estimated 650,000 cases of MDR-TB around the world in 2010 (Walter, Strong
et al. 2012). The actual number of cases may be a lot greater since surveillance for MDRTB is inadequate because of the lack of laboratory resources around the world for testing
drug sensitivity. This is a problem that not only affects developing nations, but is a threat
to the control of TB in developed nations.
Public Health Importance
MDR-TB is a growing threat to the United States (US). In 2011, it was reported
by the Centers for Disease Control and Prevention (CDC) that 9.2% of TB cases in the
US were resistant to one first-line TB drug and 1.3% was resistant to more than one drug
(ALA 2013). The number of MDR-TB cases in the US is increasing each year. This study
will help to determine associations between MDR-TB and some of its social and
behavioral risk factors. It is important to look at the social risk factors for MDR-TB
because they help us better understand the behaviors of individuals that lead to the
disease and how these behaviors can be altered. The CDC tracks many of these variables
in their Online Tuberculosis Information System (OTIS) Database. Literature also shows
these variables to be the ones associated with higher rates of MDR-TB elsewhere in the
world. Therefore, it would be ideal to focus on how these variables are associated with
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MDR-TB. The aim is to find the variables associated with MDR-TB in order to set up
prevention programs for the future. This study hopes to be the first step in that process.

1a. Study Objective
Developed nations, such as the United States, have set procedures and resources
that help control tuberculosis. However, MDR-TB is a threat to these TB control
measures. This study will look at the social determinants of MDR-TB compared to those
of TB in the United States from 2005 to 2009. This association has not been one that has
been explored before. The study will look at the association of MDR-TB with the
variables of occupation; place of birth; HIV status; homelessness in the past year; and
whether or not the person lived in a correctional facility and stratify them with age, sex,
race, and a combination of the three. These specific variables are tracked annually by the
CDC. If associations are found, public health officials can focus on specific behaviors
related to these variables and set up programs that better prevent MDR-TB.
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1c. Research Question
Is there an association between specific risk factors and the rates of multidrug resistant
tuberculosis in the United States?

Can the analysis of the data provide a model to predict multidrug resistant rates in the
United States?

How can the answers to the previous two questions be used to formulate interventions
and possibly come up with solutions to the problem of multidrug resistant tuberculosis in
the United States?

3

CHAPTER 2
LITERATURE REVIEW
2a. Background of TB
Tuberculosis (TB) is a disease that is caused by the bacterium Mybacterium
tuberculosis. It usually manifests as a respiratory illness, but can present in other areas of
the body as well such as joints, kidneys, and the brain. If it is not treated properly, it can
be fatal.
TB is a highly contagious disease that is spread through the air. One must inhale
the infectious droplets to become infected. However, TB is not spread through person-toperson physical contact, sharing bodily fluids, or touching infected surfaces.
Tuberculosis is an ancient disease that can be traced back to the time before
humans. The genus Mycobacterium is thought to have originated more than 150 million
years ago during the Jurassic period (Daniel 2006). Reports show that an early
predecessor of M. tuberculosis may have infected early hominids as far back as 3 million
years ago in present East Africa. However, modern strains of M. tuberculosis are thought
to have originated about 20,000-15,000 years ago (Daniel 2006). Knowing the mutation
rate of M. tuberculosis, scientists have concluded that a lot of present diversity among the
strains of this bacterium came about between 2,500-1,000 years ago. Egyptian mummies
from more than 5,000 years ago show skeletal abnormalities typically associated with
tuberculosis. The art from this era also depicts the ailments associated with tuberculosis.
However, there are very limited written records of tuberculosis in ancient Egypt. The
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Bible also mentions tuberculosis using the ancient Hebrew word “schachepheth.”
Peruvian mummies show archaeological evidence of tuberculosis in the Americas.
During the middle ages, though written records of tuberculosis became hard to find, the
phenomenon of the “royal touch” became widespread in Europe. The royal touch
consisted of monarchs touching individuals with tuberculosis in hopes of curing them
(Daniel 2006).
During the Renaissance, knowledge of tuberculosis began to change. René
Théophile Hyacinthe Laennec clarified the pathogenesis of the disease, unified the
concept of pulmonary and extrapulmonary TB, and described the physical symptoms of it
(Daniel 2006). Laennec’s exposition pioneered the modern understanding of tuberculosis.
During this era, tuberculosis had reached epidemic levels across Europe and society
began romanticizing the disease. People with TB were said to be interesting and
melancholy. Many authors of the time, such as Emily Brontë, described their tuberculosis
characters as, “young and fresh.” Many other examples of this romanticism of TB can be
found in the works of Charles Dickens and Lord Byron and in the descriptions of
important figures of the time.
On March 24, 1882, the history of tuberculosis changed when Hermann Heinrich
Robert Koch made his famous presentation, Die Aetiologie der Tuberculose. His
presentation identified his famous postulates, known as the Koch-Henle postulates, which
are still the standard for identifying infectious disease causality. In 1909, pediatrician
Clemens Freiherr von Pirquet introduced the term “latent tuberculosis,” when he
5

published a study of tuberculin reactions that showed positive tuberculin reactions in
children who did not have symptoms of tuberculosis. Charles Mantoux introduced the use
of needles and syringes to inject tuberculin into the skin. Florence Seibert was the one
who developed purified protein derivative (PPD) in 1908 in fundamentally the same form
it is used today. PPDs were used to establish the commonality of latent TB infection in
the United States. In 1921, Albert Calmette and Camille Guérin developed a vaccine for
tuberculosis called the BCG (Bacille Calmette-Guérin). Over the next decade, the vaccine
was used to protect hundreds of thousands of children from TB infection. However, BCG
was not widely used in the United States, where treatment of latent infection was more
emphasized (Daniel 2006). The 1950s brought about the biggest advances in tuberculosis
with the development of treatment drugs. In 1950, the British Journal of Tuberculosis and
Diseases of the Chest reported the first case of streptomycin as treatment. The first oral
anti-tuberculosis drug, Isoniazid, followed in 1952, with rifamycin in 1957. Tuberculosis
control entered a new era with the introduction of these treatments. The next section will
describe the symptoms of TB, along with the treatments in the new era.
Once a person becomes infected with the TB bacteria, they develop one of two
conditions: latent TB infection and active TB disease. Latent TB infection is when M.
tuberculosis lives in the body without causing any symptoms. The infected person is not
infectious and cannot spread TB during this phase and is said to have Latent TB Infection
(LTBI). But, the TB bacteria can become active at any time and cause active TB disease.
When a person has active TB disease, the M. tuberculosis is actively spreading through
6

their body. The site of the infection determines the symptoms that a person experiences.
For pulmonary TB, the symptoms include a bad cough lasting three weeks or more, chest
pain, weight loss, weakness or fatigue, loss of appetite, blood or sputum in the cough,
chills, fever, and night sweats.
There are many ways to diagnose tuberculosis. The most common is a TB skin
test, often referred to as a TST or PPD. It is performed by injecting a small amount of the
liquid tuberculin under the skin in the forearm. The patient must then wait between 48-72
hours to have their area checked by a health professional. The healthcare worker checks
to see the reaction the person has had. The area is checked for a hard raised area and then
measure the diameter of the area, if present. Whether or not the result is positive depends
on the size of the induration. An induration greater than 10 mm is indicative of a positive
diagnosis. The diagnosis is influenced by a person’s age and their risk for contracting TB.
A positive test means the person either has active or latent TB infection and further tests
need to be done to determine which. A negative skin test means that the person’s body
did not react to the test, and it is unlikely that they are infected with TB (CDC, 2012).
However, in some cases, these people may still be infected with TB and must be
diagnosed using their symptoms. These people are referred to as anergic.
Tuberculosis may also be diagnosed with a blood test, called interferon-gamma
release assays or IGRAs. This test is a blood test that measures how the immune system
reacts to the TB bacteria. Like the TSTs, a positive test means the person is likely
infected with active or latent TB and further tests need to be done to determine exactly
7

which one. A negative IGRA means it is not likely the person is infected with TB disease.
IGRAs are preferred to TSTs in the case that a patient has received bacille CalmetteGuérin (BCG), which is a TB vaccine, or a patient is not able to return to have their TST
evaluated (CDC, 2012).
Treatment for tuberculosis is based on the type of TB a patient has. The goal of
latent TB treatment is to prevent the patient from developing active TB disease. Latent
TB infections are treated with one of four regimens suited to meet their needs. All four of
the regimens include different variations of the medications isoniazid (INH), rifampin
(RIF), and rifapentine (RPT) for various durations (CDC, 2012).
Treatment for active tuberculosis is more extreme since these people have
significantly greater numbers of TB bacteria in their bodies. Currently, there are 10 drugs
on the market that are approved for the treatment of TB. However, the main four that are
used as the front-line drugs are isoniazid (INH), rifampin (RIF), ethambutol (EMB), and
pyrazinamide (PZA). The treatment regimens last 6-9 months, with the first two months
known as the initial phase, followed by a continuation phase lasting from 4 to 7 months.
It is imperative that patients complete their drug regimens because failing to do so can
lead to re-infection or drug resistance (CDC, 2012).
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2b. Background of MDR-TB
MDR-TB is caused by strains of Mybacterium tuberculosis that are resistant to at
least isoniazid and rifampicin, two of the most powerful first-line drugs to combat TB
(Migliori, D'Arcy Richardson et al. 2009). Molecular epidemiological techniques have
shown that the M. tuberculosis strain known as the “Beijing,” is responsible for MDR-TB
outbreaks in countries with lower rates of TB, such as the United States (Drobniewski,
Balabanova et al. 2005). In addition to the great global threat that the disease poses, it
can also lead to the more deadly extensively drug-resistant TB (XDR-TB). XDR-TB is
caused by Myobacteria that meet the same requirements as MDR-TB, but are also
resistant to any fluroquinolone and to at least 1 of 3 anti-TB injectable drugs:
capreomycin, amikacin, or kanamycin (Migliori, D'Arcy Richardson et al. 2009). As is
to be expected, the mortality for both of these forms of TB is high. Among XDR-TB
patients, mortality rates are similar to the pre-antibiotic era (Ershova, Kurbatova et al.
2012).
MDR-TB and XDR-TB can occur for many different reasons. First, it may be due
to the providers. They may prescribe inadequate drug regimens for patients, whether it
be not enough doses, not enough drugs, the incorrect drugs, or a too short treatment time.
The second reason may come down to the patients. They may not follow their drug
regimens as prescribed. Third, the drugs used to treat TB may not be of good quality
(Migliori, D'Arcy Richardson et al. 2009).
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The second reason listed above, patients not following their drug regimens as
prescribed, will be the focus of this study. Finding out the factors that hinder patients
from correctly taking their medication is imperative. Once those factors are known, steps
can be taken to help in those situations and prevention programs can be set up. As will be
explained later, prevention is a key factor in the fight against MDR-TB in this nation.
MDR-TB and XDR-TB are either primary or acquired. Primary drug resistance
takes place when MDR-TB or XDR-TB is directly transmitted from one individual to
another. Acquired drug resistance may happen through the incorrect use of TB drugs.
(Migliori, D'Arcy Richardson et al. 2009).
The issue of drug resistance to TB was first realized shortly after streptomycin
was introduced in 1944. The first reported death from a drug-resistant strain of TB was
reported by the British Medical Research Council in 1948. This led to the discovery in
the late 1940s that combination therapy with both streptomycin and para-aminosalycilic
acid was an effective treatment for the emerging drug-resistant strains. However, the
duration of this treatment regimen was markedly long. Beginning in 1952, the
introduction of INH, RIF, EMB, and PZA kept the problem in check until the 1980s. In
the early 1990s, however, there began several outbreaks of MDR-TB, particularly among
Human Immunodeficiency Virus (HIV)-infected patients, that brought this problem back
to the forefront as a major global public health issue (Nguy, Shui et al. 2009). The most
well-known of these outbreaks was a cluster that took place in one Florida hospital and
three New York City hospitals from 1990 to 1992. These outbreaks had mortality rates
10

between 72% and 83% among HIV positive patients. These outbreaks led to an overhaul
in the way MDR-TB was reported on in the country and allowed for population-based
analysis of the disease (Migliori, D'Arcy Richardson et al. 2009).
Multidrug resistant tuberculosis is diagnosed using drug susceptibility testing
(DST). DST is a difficult procedure to perform and standardize because it requires the
knowledge of the origins of the drug resistance and the conditions surrounding it; potency
and stability of drugs in the lab; antimycobacterial activity of the drugs in different
testing mediums; and reading interpretation of the results. From start to finish, the test
takes one month to complete and may only be done once a TB diagnosis has been
established. It also requires a live growing organism. DST must also be done for firstand second-line drugs separately (CDC 2010). DST is a long, complicated, and expensive
process and usually only given to patients of high priority (Manjourides, Lin et al. 2012).
Therefore, prevention is key when it comes to MDR-TB.

2c. Treatment of MDR-TB
Treatment of MDR-TB is an arduous and expensive process. It can take up to two
years to treat with drugs that are less potent and more toxic than regular TB drugs
(Jenkins, Zignol et al. 2011). The drug regimen for treating drug-resistant TB depends on
the exact drugs the patient is resistant to. The drugs that can be used as part of the
treatment regimen are isoniazid (INH); rifampin (RIF); pyrazinamide (PZA); ethambutol
(EMB); streptomycin (SM); ciprofloxacin or ofloxacin or moxifloxacin or gatifloxacin
11

(FQ); injectable agents like SM or kanamycin or amikacin or capreomycin or viomycin;
and second-line drugs such as rifabutin, ethionamide, prothionamide, para-amino
salicylic acid, D-cycloserine and thiacetazone. Treatment regimens can include anywhere
from three to many of these drugs at a time and last anywhere from six months to over
two years (Ahmad, Suhail et al. 2010). Patients must be closely monitored to ensure they
follow the treatment regimen exactly. The outcome of the treatment depends on the type
of drug-resistance, the availability of the previously listed drugs, and the patient’s
adherence to the therapy (Migliori, D'Arcy Richardson et al. 2009).
In extreme cases, surgical resection of the infected lung tissue has been used as
treatment. This treatment method is only used in cases with severe drug resistance with a
high probability of medication therapy failing, localized disease with good postoperative
expectations for lung function, and ample activity of TB drugs to ensure proper healing
of the surgery stump. Surgical measures should only be offered after medication
treatment has been tried for at least three months (Migliori, D'Arcy Richardson et al.
2009).

2d. Risk Factors for MDR-TB
There are many different risk factors for multi-drug resistant TB. A survey done
by Casal, et. al. identified immigration, aging, HIV infection, population mobility, living
in communities, and drug abuse as possible factors in Western European countries (Casal,
Vaquero et al. 2005).
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HIV
When tuberculosis drugs became available in the 1950s, the disease began a steady
decline in Western countries. However, TB re-emerged with the advent of human
immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS)
(Breathnach, de Ruiter et al. 1998). Shenoi et al. estimated that as of 2009, there were 1214 million people coinfected with HIV and M. tuberculosis. They also stated that TB is
the most common opportunistic infection among HIV patients (Shenoi, Heysell et al.
2009). The CDC states that as of July 2012, a quarter of all HIV/AIDS deaths can be
attributed to TB (2012). HIV lowers an individual’s ability to fight off infection, making
them more susceptible to not only regular TB, but MDR-TB and XDR-TB as well.
HIV/AIDS has been associated with the malabsorption of TB drugs, which may
contribute to higher rates of drug-resistance (Andrews, Shah et al. 2010). A crosssectional, country-wide study done in Estonia found that HIV-infected patients are three
times more likely to develop extensively drug-resistant tuberculosis than those not
infected with HIV (Kliiman and Altraja 2009). In Ukraine, it was found that HIV patients
are at a higher risk for developing multidrug-resistant TB during their first occurrence of
TB, which differs from non-HIV patients (Shenoi, Sheela et al. 2009).
Patients infected with HIV are not only more likely to develop MDR-TB; they also
have higher rates of mortality from the disease. Between the years 1993 and 2007, 26
deaths occurred from XDR-TB in the U.S. Out of these deaths, 21 were confirmed HIVpositive cases (Migliori, D'Arcy Richardson et al. 2009). Mortality rates in North
13

America have ranged from 70-90% with a median survival time ranging from 4-6 weeks
from diagnosis to death (Kelleher, Coakley et al. 1996).
One of the biggest issues facing the coinfection of multidrug-resistant TB and HIV is
the inability to get a rapid TB diagnosis and then subsequently determine drug
susceptibility. The patients must wait for a diagnosis, and in the meantime, they not only
spread disease but they also are given inadequate treatment. In South Africa, most
patients with XDR-TB die before their results come back and even before they have had
a chance to be tested for drug resistance (Shenoi, Sheela et al. 2009). This issue is mainly
one in developing nations, but can affect the developed world in areas where adequate
TB diagnostic tools do not exist.
Co-infection of MDR/XDR TB and HIV can also have a great impact on the HIV
epidemic. Shenoi et al. listed ten ways drug-resistant TB can affect HIV:
1) higher risk of drug-resistant TB compared to patients not infected with HIV;
2) higher mortality rates for co-infected individuals;
3) potential side effects from combing secondline TB drugs and antiretrovirals (ARVs);
4) hospital-related transmission of drug-resistant TB to HIV patients;
5) risk to healthcare workers dealing with HIV patients;
6) strain on national TB and DOT programs;
7) demand exceeding the amount of available laboratory services and specialized
treatment referral;
8) competition for resources between TB and HIV programs;
9) greater stigma for co-infected patients;
14

10) general undoing of gains made in HIV epidemic from ARVs (Shenoi, Sheela et al.
2009).
The evidence for an association between MDR-TB and HIV is strong. However, no
study has measured the association within the same parameters and the same time frame
that this study will.

Previous TB Infection
A well-established risk factor of multidrug-resistant TB is prior TB infection
(Andrews, Shah et al. 2010). One study put the rate of acquired resistant as high as 20%
for previous cases, with 4-10% going on to develop full-fledged MDR-TB (Casal,
Vaquero et al. 2005). According to a study done by Tracy Dalton across Estonia, Latvia,
Peru, the Philippines, Russia, South Africa, South Korea, Thailand, and Taiwan, a history
of TB was the strongest risk factor for MDR-TB, with the overall value of 93.8%
probability (Hoffner). The risk only increases the more times a person is treated for TB
(Zhao, Xu et al. 2012) or the longer their treatment regimen lasts (Migliori, D'Arcy
Richardson et al. 2009). These results show the importance of programs such as directly
observed therapy (DOT), where patients are monitored while they take TB medications to
ensure the regimen is being followed correctly and having the desired outcomes. DOT
helps cure most cases and prevents the development of chronic cases, which can go on to
become drug resistant (Casal, Vaquero et al. 2005). Many of the variables studied in this
15

thesis are not only risk factors for MDR-TB; they are also risk factors for regular TB.
This, as this section states, is itself a risk factor for MDR-TB.

US-born versus Foreign-born
Global migration and travel have had an immense impact on TB in the United States.
It was reported that between 2001 and 2008, 54.6% (62,364) of the new TB cases in the
U. S. were diagnosed among foreign-born patients. Of this, 249 cases were MDR-TB
cases (Liu, Painter et al. 2012). More recent statistics state that foreign-born cases are
now responsible for 80% of the MDR-TB cases in the U.S. (Migliori, D'Arcy Richardson
et al. 2009). Table 1 provides the exact statistics from 1993. A recent study reported that
active pulmonary TB was diagnosed in 7.0% of refugees and immigrants in the United
States when these same patients had smear-negative diagnoses before arrival to the
country (Liu, Painter et al. 2012). Therefore, it can be concluded from this study that at
least some immigrants and refugees are acquiring the disease upon entering the country.
Finding this association is important because then, the reasons behind the association can
be explored.
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Table 2.1 Incidence of MDR-TB in the United States among new cases according to
place of birth, 1993-2007
New MDR-TB Cases
Year

Total

United States-born (%)

Foreign-born (%)

1993

407

301 (74)

103 (26)

1994

353

238 (67)

110 (33)

1995

254

169 (67)

85 (33)

1996

207

105 (51)

101 (49)

1997

155

76 (49)

79 (51)

1998

132

55 (42)

76 (58)

1999

127

39 (31)

88 (69)

2000

120

38 (32)

82 (68)

2001

118

34 (29)

84 (71)

2002

130

36 (28)

94 (72)

2003

92

24 (26)

68 (74)

2004

102

26 (25)

76 (75)

2005

98

19 (19)

78 (81)

2006

94

17 (18)

77 (82)

2007

98

20 (20)

78 (80)

Adapted from : (Migliori, D'Arcy Richardson et al. 2009)
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Hospitalization
Some studies have shown hospitalization as a risk factor for MDR-TB. A study
conducted in South Africa by Andrews, Shah, et al concluded that a prolonged hospital
stay is associated with a 3-fold increase in the risk of contracting MDR-TB (Andrews,
Shah et al. 2010). Another recent study suggested that MDR-TB patients that were
treated with first-line drugs were responsible for the majority of TB spread in a
tuberculosis ward of the hospital (Escombe, Moore et al. 2008). Gandhi, Weissman et al.
used social network analysis to study XDR-TB and concluded that rather than an
outbreak starting from a single patient, there is a high degree of interconnectedness
among hospital patients. The study also stated that the long delay in diagnosing XDR-TB
patients contributed to transmission since it gave unrecognized patients time and
opportunity to infect others in congregation areas. (Gandhi, Weissman et al. 2013).

Poverty
As stated earlier, homelessness has been associated with MDR-TB and XDR-TB. The
homeless live in poor conditions and are usually malnourished from reduced access to
food. They also have reduced access to healthcare. This prolongs their period of
infectiousness, increasing their risk of transmission to their peers. The homeless also have
higher rates of defaulting from their treatment, thus increasing their risk for drug-resistant
TB (Migliori, D'Arcy Richardson et al. 2009). Poverty is also linked to higher rates of
incarceration. Prisons have reported higher rates of drug-resistant strains of tuberculosis
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due to overcrowding and the inability to isolate the resistant cases (Migliori, D'Arcy
Richardson et al. 2009).

Race
Many studies have linked race to multidrug resistant TB. A study conducted in Texas
stated that US-born blacks are more likely than US-born whites to not only have drugresistant forms for tuberculosis; they are also more likely to have a lot of the risk factors
for MDR-TB (Serpa, Teeter et al. 2009). The study went on to explain that
socioeconomic characteristics are linked to race and therefore explain the disparity in TB
rates.

Age
Age may be a risk factor for MDR-TB. A disproportionate number of older adults
are affected by all forms of TB due the weakening of their immune systems with age.
They are also more likely to be afflicted with illness such as diabetes mellitus, renal
disease, and silicosis, which increases the risk of progressing from LTBI to active TB
disease. Certain medications taken by older adults, such as corticosteroids and transplant
suppression drugs, also accelerate the progression to active disease (Pratt, Winston et al.
2011). Also, just being older and being around peers who are more susceptible to TB
increases risk. With increased risk of TB comes increased risk of drug resistant forms.
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The literature shows that all of the previously listed variables may be associated
with higher rates of MDR-TB. Therefore, it was important for this study to include as
many of them as possible in data analysis and test the associations for the sample
population. The next chapter will explain the methodology of this data analysis.
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CHAPTER 3
METHODS
The main objective of this study was to find the association between certain social
determinants and multidrug-resistant tuberculosis in the United States. The variables that
were examined were whether or not the patient lived in a correctional facility at the time
of diagnosis; HIV status; homelessness; whether or not the patient had an occupation; and
place of birth (US-born or foreign born), all between the years of 2005 and 2009. Each
variable was cross-tabulated with MDR-TB to find the crude odds ratio (OR). Each crude
OR was then each stratified by age; sex; race; age and race; age and sex; and age, sex,
and race to find if any of the strata were confounders between the variable in question
and MDR-TB.

3a. Data Sources
All of the data were obtained from the CDC Online Tuberculosis Information
System (OTIS). OTIS contains information on verified TB cases as reported to the CDC
by state health departments, the District of Columbia, and Puerto Rico from 1993 to
2010. The data is extracted using the CDC national TB surveillance system. This
database is updated annually and includes data for 26 variables that can be crossstratified. Users can obtain charts, graphs, and tables and extract the data for the available
variables.
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3b. Study Population
The study population was the US population, including all 50 states and the
District of Columbia. All races/ethnicities, genders, and ages were incorporated.

3c. Statistical Analysis
The OTIS database does not allow for raw data to be extracted. Therefore, it was
impossible to use statistical analysis software to examine the data. Instead, each variable
was cross-tabulated with MDR-TB and then stratified by race/ethnicity, sex, and age.
First, each association was stratified by age; then sex, then race independently; then by
both age and race; then by both age and sex, and lastly by age, sex, and race. The
race/ethnic groups the data were classified in are Non-Hispanic Whites; Hispanics; NonHispanic Blacks or African Americans; and Other, which included Non-Hispanic Native
Americans and Non-Hispanic Asians and/or Pacific Islanders. The sexes were classified
into male and female. The ages were grouped by 0-24 years of age and 25 and above.
For all of the variables, only the Yes/No results were used. Therefore, only the variables
that could be put into a 2x2 Yes/No table were able to be included. All of the
indeterminate and not reported data were ignored. The stratification was done in OTIS,
after which the data were transferred to Microsoft Excel (version 2010). From there, the
data were put into 2x2 tables to calculate odds ratios and Mantel-Haenszel odds ratios to
find associations between the variables and MDR-TB and to decipher if any of the
variables were confounded by the different stratifications of age, sex, and race.
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CHAPTER 4
RESULTS

The main purpose of this study was to find the social determinants of multidrugresistant tuberculosis in the United States. To find the association, if any, between certain
variables and MDR-TB, the Mantel-Haenszel odds ratio (ORmh) was calculated. Below
are the results for each of the following variables as tested against MDR-TB:
1) Whether or not the patient was in a correctional facility
2) HIV Status
3) Homelessness
4) Whether or not the patient had an occupation
5) Place of birth
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Correctional Facility vs. MDR-TB

Table 4.1 Results of Correctional Facility vs. MDR-TB
EXPOSURE
Crude OR = 1.757
Age
Sex
Race
Age, Race
Age, Sex
Age, Sex, Race

ORMH

EFFECT
MODIFICATION
----------------------------1.793 Negative Confounding Present
1.581 Positive Confounding Present
1.436 Positive Confounding Present
1.442 Positive Confounding Present
1.612 Positive Confounding Present
1.361 Positive Confounding Present

These calculations were testing the association between living in a correctional
facility and having MDR-TB. The crude OR for this association is 1.757, meaning that
those that resided in a correctional facility in the past year have a 75% increase in the
odds of developing MDR-TB than those who did not reside in a correctional facility in
the past year. However, as this association was further stratified, it showed different
results. Age was shown to be a negative confounder for the association between living in
a correctional facility and having MDR-TB. Negative confounding means that the OR is
falsely lowered. Further stratification by sex; race; age and race; age and sex; and age,
sex, and race showed that these strata are positive confounders for the association
between living in a correctional facility and having MDR-TB. Positive confounding
means that the OR is falsely elevated. All of the strata showed effect modification;
meaning that the different groups (i.e. different age groups, different racial groups, males
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and females) had different risk estimates for the association between living in a
correctional facility and having MDR-TB.

HIV Status vs. MDR-TB

Table 4.2 Results of HIV Status vs. MDR-TB
EXPOSURE
Crude OR = 0.764
Age
Sex
Race
Age, Race
Age, Sex
Age, Sex, Race

ORMH

0.692
0.741
0.569
0.522
0.678
0.511

--------------Positive Confounding
Positive Confounding
Positive Confounding
Positive Confounding
Positive Confounding
Positive Confounding

EFFECT
MODIFICATION
--------------No Effect Modification
Present
Present
Present
Present
Present

The crude OR for the association between HIV and MDR-TB showed a surprising
result. It showed that those with HIV were about 25% less likely to have MDR-TB than
those without HIV. Each stratification showed positive confounding, meaning that when
stratified with those variables, the ORs were falsely elevated and should have been lower.
Effect modification was present in all of the strata except age, meaning that the risk
estimates for age were the same but were different for all of the other strata.
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Homeless vs. MDR-TB

Table 4.3 Results of Homeless vs. MDR-TB
EXPOSURE
Crude OR = 1.157
Age
Sex
Race
Age, Race
Age, Sex
Age, Sex, Race

ORMH

1.086
1.052
0.864
0.811
1.004
0.783

--------------Positive Confounding
Positive Confounding
Positive Confounding
Positive Confounding
Positive Confounding
Positive Confounding

EFFECT
MODIFICATION
--------------Present
Present
Present
Present
Present
Present

This set of calculations tested the association between being homeless and having
MDR-TB. The crude OR showed the homeless are 15% more likely to have MDR-TB
than those that are not homeless. However, all of the strata showed positive confounding
and effect modification.

Occupation vs. MDR-TB

Table 4.4 Results of Occupation vs. MDR-TB
EXPOSURE
Crude OR = 0.990
Age
Sex

ORMH

EFFECT
MODIFICATION
----------------------------1.004 Negative Confounding Present
0.957 Positive Confounding Present
26

1.050 Negative Confounding Present
Race
1.056 Negative Confounding Present
Age, Race
0.970 Positive Confounding Present
Age, Sex
1.030 Negative Confounding Present
Age, Sex, Race
The crude OR for the association between having an occupation and having
MDR-TB was 0.990. Since this OR is so close to 1, it means that both groups (those with
an occupation and those without) have almost the same odds of getting MDR-TB. The
different strata showed various results. When this association was further stratified by
age; race; age and race; and age, sex, and race, these strata were shown to be negative
confounders, meaning that the OR was falsely lowered. However, stratification by sex
and by both age and sex showed these respective strata to be positive confounders,
meaning they falsely elevated the OR. Effect modification was present for all of the
strata.

Place of Birth vs. MDR-TB

Table 4.5 Results of Place of Birth vs. MDR-TB
EXPOSURE
Crude OR = 0.292
Age
Sex
Race
Age, Race
Age, Sex
Age, Sex, Race

ORMH

EFFECT
MODIFICATION
----------------------------0.299 No Confounding
Present
0.296 No Confounding
Present
0.413 Negative Confounding Present
0.377 Negative Confounding Present
0.299 No Confounding
Present
0.400 Negative Confounding Present
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When calculating the association between place of birth and having MDR-TB, the
crude OR was 0.292. This means that those that were US-born were about 70% less
likely to have MDR-TB than those that were foreign-born. When further stratified by age,
sex, and by both age and sex, there was no confounding. Meaning that these three strata
were not confounders in the relationship between place of birth and having MDR-TB.
When stratifying by race; age and race; and age, sex, and race, there was negative
confounding, showing that the OR was falsely lowered. Effect modification was once
again present in all strata.
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CHAPTER 5
DISCUSSION
The main objective of this study was to find the social determinants of multidrug
resistant TB in the US. The variables that were examined and tested against the rates of
MDR-TB were whether or not the patient was in a correctional facility; HIV status;
homelessness; occupation; and place of birth. These variables were then stratified by
race, sex, and age to find associations. The specific research questions asked were:

Is there a correlation between specific risk factors and the rates of multidrug resistant
tuberculosis in the United States versus drug-treatable tuberculosis?

Can the analysis of the data provide a model to predict multidrug resistant rates in the
United States?

How can the answers to the previous two questions be used to formulate interventions
and possibly come up with solutions to the problem of multidrug resistant tuberculosis in
the United States.
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Confounding is a difficult phenomenon to understand and explain. A confounding
variable is usually related to both the independent and dependent variables, thus affecting
the relationship between the variables. There could be several reasons why a certain
characteristic is a confounder. The next section will attempt to explain the disparities in
the results as each variable was tested against MDR-TB.
When looking at the association between having lived in a correctional facility in
the past year and MDR-TB, the unadjusted odds ratio showed that those who have lived
in a correctional facility in the past year are 75% more likely to have MDR-TB than those
who did not live in a correctional facility. A study done by Dalton et al. reinforced this
result. The study was a prospective cohort study evaluating the prevalence and the risk
factors of MDR-TB in eight different countries. They concluded that resistance to
second-line injectable TB drugs was associated with imprisonment (Dalton, Cegielski et
al.). Internationally, TB prevalence in prisons is high; as is transmission of resistant
strains. This could be explained by prison overcrowding and the inability of these prisons
to isolate the resistant cases (Migliori, D'Arcy Richardson et al. 2009). However, all of
the strata were shown to be confounders for the association between living in a
correctional facility and having MDR-TB, meaning that the MDR-TB could be due to
either living in a correctional facility or due to age, sex, race, or a combination of the
three. Future studies would have to control for these variables when testing the
relationship between living in a correctional facility versus having MDR-TB.
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With a crude OR of 0.764, the association between HIV and MDR-TB was shown
to be protective. Those with HIV were shown to be 25% less likely to have MDR-TB
than those without HIV. This was surprising since most of the literature suggested the
opposite. Some of the literature even went as far as to suggest that there is an epidemic of
HIV and MDR-TB coinfection (Shenoi, Heysell et al. 2009). It may be that the unusual
results that were achieved pertain only to the sample population. In a study done in the
country of Georgia, it was found that HIV and AIDS both were not associated with the
development of drug-resistant TB (Vashakidze, Salakaia et al. 2009). Another casecontrol study about the risk factors for MDR-TB in four European countries also
concluded that HIV status did not prove to be a statistically significant risk factor for
MDR-TB at the European level. Suchindran et al. also state that not a single study from
Africa showed an association between HIV and MDR-TB and that results from other
regions were also conflicting (Suchindran, Brouwer et al. 2009). Again, further studies
would have to be conducted in the United States to ascertain if HIV and MDR-TB are
associated or not.
When looking at the association between homelessness and MDR-TB, the results
showed that homeless people were 15% more likely to have MDR-TB than those that
were not homeless. Literature showed an association between being homeless and having
XDR-TB, but not MDR-TB. However, since XDR-TB is a more severe form of MDRTB, the explanations for the associations can be similar. Homeless people live in poor
conditions and are often malnourished. They have less access to healthcare and are more
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likely to default from treatment. Homelessness is also associated with alcohol abuse,
which has been shown by many studies to be associated with higher rates of MDR-TB
(Migliori, D'Arcy Richardson et al. 2009). Kliiman et al. also found homelessness to be
an independent risk factor for MDR-TB (Kliiman and Altraja 2009).
The unadjusted OR for the relationship between having and occupation and
having MDR-TB was 0.990. This OR was so close to 1 that it means both groups, those
with an occupation and those without, have about the same risk for getting MDR-TB.
While the literature did not mention having or not having an occupation as a risk factor
for MDR-TB, it did mention poor living conditions as a factor. Poor living conditions
usually come about when one does not have a source of income, i.e. a job.
The last variable that was tested was place of birth versus MDR-TB. The crude
OR showed that the US-born were about 70% less likely to get MDR-TB than those that
were foreign-born. TB rates among foreign-born that have recently arrived to the US
continue to remain very high (Liu, Painter et al. 2012). A study done in California found
that most MDR-TB cases in the US are related to the migration of those who have
already been infected with MDR-TB (Metcalfe, Kim et al. 2010). These results show that
better screening procedures and treatment options should be made available for newly
arrived persons to the US.
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Limitations
There were several limitations to this study. The main limitation was the database
that was used. The OTIS database did not provide raw data. The lack of these data did not
allow for full testing of association. The testing that was done had to be done by hand.
Therefore, human error should also be taken into account. The data did not provide
information on other social determinants such as socioeconomic status, alcohol abuse,
hospitalization, etc. that would have been helpful in explaining MDR-TB rates. The
study was also limited by its use of secondary data, as opposed to primary data.

Conclusions and Recommendations
The study tested five variables against MDR-TB to find association measures
according to age, sex, and race. The evidence showed these three strata and combinations
of the three to be confounders for the separate variables and MDR-TB.
The results of the calculations and the literature showed that it is important to
control and strive to improve the situation of MDR-TB. Further testing of the variables
that lead to MDR-TB should be done in the sample population and expanded populations
to help find ways to prevent the disease. Improved treatment regimens for MDR-TB that
include less toxic drugs, shorter treatment durations, and generally more efficient drugs
should be developed (Walter, Strong et al. 2012). Studying the mechanism of mutation
to develop drugs that are more targeted to treated resistant strains of M. tuberculosis
would help with this endeavor (Walter, Strong et al. 2012). New anti-TB drugs should be
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developed for all forms of TB and randomized control trials should be used to evaluate
them (Walter, Strong et al. 2012). Better ways of testing for tuberculosis should be
established that provide faster diagnoses (Walter, Strong et al. 2012). Another factor that
would help improve MDR-TB rates would be to increase drug resistance testing before
treatment begins (Zhao, Xu et al. 2012). Making sure TB treatment is completed is also
imperative. Directly observed therapy programs should be in place to ensure patients are
completing their drug regimens. All of these suggestions would help WHO of achieving
its goal of eradicating all forms of TB by the year 2050.

34

REFERENCES

(2013). "Multidrug resistant (MDR TB) fact sheet." American Lung Association.
Retrieved from http://www.lung.org/lung-disease/tuberculosis/factsheets/multidrugresistant.html
(2010). "Drug susceptibilty testing." Centers for Disease Control and Prevention.
Retrieved from http://www.cdc.gov/tb/topic/laboratory/Drug_testing.htm
(2012). "CDC Grand Rounds: the TB/HIV syndemic." Morbidity and mortality weekly
report 61(26): 484-489.
(2012). "HIV in the United States: at a glance." Centers for Disease Control and
Prevention. Retrieved from http://www.cdc.gov/hiv/resources/factsheets/us.htm
Ahmad, S., & Mokaddas, E. (2010). Drug-resistant tuberculosis: causes, diagnosis and
treatment. In Nguy, S. & K'ung, Z (Eds.), Drug-resistant tuberculosis causes, diagnosis
and treatments (1-58). New York: Nova Science Publishers, Inc.
Andrews, J., N. S. Shah, et al. (2010). "Predictors of multidrug- and extensively drugresistant tuberculosis in a high HIV prevalence community." PLoS ONE 5(12): e15735e15735.
Basu, S., G. Friedland, et al. (2009). "Averting epidemics of extensively drug-resistant
tuberculosis." Proceedings of the National Academy of Sciences of the United States of
America 106(18): 7672-7677.
Berg, M. T., and DeLisi, M. (2006). "The correctional melting pot: race, ethnicity,
citizenship, and prison violence." Journal of Criminal Justice 34: 631-642.
Bishai, J., W. Bishai, et al. (2010). "Heightened vulnerability to MDR-TB epidemics after
controlling drug-susceptible TB." PLoS ONE 5(9): e12843-e12843.
Breathnach, A. S., A. de Ruiter, et al. (1998). "An outbreak of multi-drug-resistant
tuberculosis in a London teaching hospital." Journal of Hospital Infection 39(2): 111-117.
Casal, M., M. Vaquero, et al. (2005). "A case-control study for multidrug-resistant
tuberculosis: risk factors in four European countries." Microbial Drug Resistance 11(1):
62-67.

35

Dalton, T., P. Cegielski, et al. "Prevalence of and risk factors for resistance to second-line
drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective
cohort study." The Lancet(0).
Daniel, T. (2006). "The history of tuberculosis." Respiratory medicine 100(11): 18621870.
Drobniewski, F., Y. Balabanova, et al. (2005). "Drug-resistant tuberculosis, clinical
virulence, and the dominance of the Beijing strain family in Russia." JAMA (Chicago,
Ill.) 293(22): 2726-2731.
Ershova, J. V., E. V. Kurbatova, et al. (2012). "Acquired resistance to second-line drugs
among persons with tuberculosis in the United States." Clinical Infectious Diseases.
Escombe, A. R., D. A. J. Moore, et al. (2008). "The infectiousness of tuberculosis
patients coinfected with HIV." PLoS Medicine 5(9): e188-e188.
Ferrer, G., C. Acuna Villaorduna, et al. (2010). "Outcomes of multidrug-resistant
tuberculosis among binational cases in El Paso, Texas." The American journal of tropical
medicine and hygiene 83(5): 1056-1058.
Gandhi, N., N. S. Shah, et al. (2010). "HIV coinfection in multidrug- and extensively
drug-resistant tuberculosis results in high early mortality." American journal of
respiratory and critical care medicine 181(1): 80-86.
Gandhi, N., D. Weissman, et al. (2013). "Nosocomial transmission of extensively drugresistant tuberculosis in a rural hospital in South Africa." The Journal of infectious
diseases 207(1): 9-17.
Hoffner, S. "Unexpected high levels of multidrug-resistant tuberculosis present new
challenges for tuberculosis control." The Lancet(0).
Jenkins, H., M. Zignol, et al. (2011). "Quantifying the burden and trends of isoniazid
resistant tuberculosis, 1994-2009." PLoS ONE 6(7): e22927-e22927.
Kelleher, P., J. Coakley, et al. (1996). "Multidrug-resistant tuberculosis in an HIVpositive man in the United Kingdom." Journal of Infection 32(2): 153-154.
Keshavjee, S. and P. Farmer (2012). "Tuberculosis, drug resistance, and the history of
modern medicine." The New England journal of medicine 367(10): 931-936.
Kliiman, K. and A. Altraja (2009). "Predictors of extensively drug-resistant pulmonary
tuberculosis." Annals of Internal Medicine 150(11): 766-775.
36

Liu, Y., J. Painter, et al. (2012). "Estimating the impact of newly arrived foreign-born
persons on tuberculosis in the United States." PLoS ONE 7(2): e32158-e32158.
Manjourides, J., H.-H. Lin, et al. (2012). "Identifying multidrug resistant tuberculosis
transmission hotspots using routinely collected data." Tuberculosis 92(3): 273-279.
Metcalfe, J., E. Kim, et al. (2010). "Determinants of multidrug-resistant tuberculosis
clusters, California, USA, 2004-2007." Emerging infectious diseases 16(9): 1403-1409.
Migliori, G., M. D'Arcy Richardson, et al. (2009). "Multidrug-resistant and extensively
drug-resistant tuberculosis in the West. Europe and United States: epidemiology,
surveillance, and control." Clinics in chest medicine 30(4): 637-665, vii.
Pratt, R., C. Winston, et al. (2011). "Tuberculosis in older adults in the United States,
1993-2008." Journal of the American Geriatrics Society 59(5): 851-857.
Serpa, J., L. Teeter, et al. (2009). "Tuberculosis disparity between US-born blacks and
whites, Houston, Texas, USA." Emerging infectious diseases 15(6): 899-904.
Shin, S., S. Keshavjee, et al. (2010). "Development of extensively drug-resistant
tuberculosis during multidrug-resistant tuberculosis treatment." American journal of
respiratory and critical care medicine 182(3): 426-432.
Suchindran, S., E. Brouwer, et al. (2009). "Is HIV infection a risk factor for multi-drug
resistant tuberculosis? A systematic review." PLoS ONE 4(5): e5561-e5561.
Vashakidze, L., A. Salakaia, et al. (2009). "Prevalence and risk factors for drug resistance
among hospitalized tuberculosis patients in Georgia." The international journal of
tuberculosis and lung disease 13(9): 1148-1153.
Walter, N., M. Strong, et al. (2012). "Translating basic science insight into public health
action for multidrug- and extensively drug-resistant tuberculosis." Respirology 17(5):
772-791.
Yong Kim, J., A. Shakow, et al. (2005). "Limited good and limited vision: multidrugresistant tuberculosis and global health policy." Social science & medicine 61(4): 847859.
Zhao, Y., S. Xu, et al. (2012). "National survey of drug-resistant tuberculosis in China."
The New England journal of medicine 366(23): 2161-2170.

37

38

